Infertility Clinical Trial
Official title:
The Role of Low Dose HCG in Improving the Quality of Antagonist Protocol in Patient Undergoing ICSI
A novel gonadotropin protocol for ovarian stimulation adds low-dose hCG (50- 200 IU) as a
source of LH (luteinizing hormone) in the late follicular phase .
This regimen reduces the number of small pre-ovulatory follicles which could reduce the risk
of OHSS(ovarian hyper stimulation syndrome). Adequate ovarian hormonal levels , oocyte
maturation, avoidance of a premature LH surge, and increased pregnancy rate are the other
benefits of this regimen.
HCG might also affect endometrial function, stimulate endometrial growth and maturation and
enhance the endometrial angiogenesis. These effects could extend the angiogenesis. These
results could lengthen the implantation Window.
Inhibin A is a heterodimer protein and does not begin to increase until just after the
increase in oestradiol in the late follicular phase, suggesting secretion by the dominant
follicle. Inhibin A secretion is regulated by LH and is associated with paracrine/autocrine
action on oocyte maturation. Moreover, it is related to follicular development and size,
serving as a marker of follicular maturation after IVF cycles .However, the role of hCG
supplementation during COH (controlled ovarian hyperstimulation)is still a matter of debate
and more studies is needed. Thus, the objective of this trial was to investigate whether LH
activity in the form of low dose hCG in GnRH (Gonadotropin releasing hormone)antagonist
cycles would improve the quality of oocytes, level of inhibin A and endometrial vascularity.
- 60 women, where 30 of them will receive low dose HCG with rFSH (group 1), while the
other 30 women will receive rFSH (Recombinant Follicle stimulating Hormone) with a
placebo (group 2) both using the antagonist protocol as a method of induction in ICSI.
- Women in both groups will be treated with a GnRH antagonist protocol with
cetrotide(cetrorelix)
- In Group 1, low dose hCG (200 IU per day) with rFSH will be given daily when at least
six follicles of 12 mm will be observed and E2 levels are higher than 600 ng/l, until
the day of the hCG trigger administration.
- Group 2 patients received rFSH injections with a placebo starting on cycle day 3 of the
stimulation cycle until the day of hCG trigger administration.
In both groups Oocytes will be retrieved 36 h after the hCG trigger shot. All mature eggs
retrieved will be fertilized with intracytoplasmic sperm injection (ICSI). Fertilization will
be checked at 18 hours post insemination. Embryo quality will be assessed and embryo transfer
will occur at day 3.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A |